Alcohol, Cirrhosis, and the Transplant Question: A Family Guide
Alcohol-related cirrhosis can improve with abstinence, and some patients come off the transplant list. What the six-month rule really means in practice.

Most families arrive here carrying the same sentence, usually secondhand: he has to be sober for six months before they will even put him on the list.
Sometimes that is close to how a particular hospital works. Often it is not. The sentence is repeated in emergency departments and family group texts until it sounds like federal law. It isn't. There is no national six-month waiting period in transplant regulation, and in 2026 several large liver programs no longer use a fixed abstinence clock as their gate at all.
What is true is harder to hold in one sentence. Cirrhosis caused by alcohol can improve substantially when drinking stops — sometimes enough that a person is removed from the waiting list because they no longer need a transplant. At the same time, alcohol-related liver disease has become the leading reason adults in the Western world receive a new liver. Families deserve the actual machinery: what the liver has to show, what the transplant team is assessing, and where the family has real leverage.
What Alcohol Actually Does to the Liver
The liver metabolizes alcohol, which is why it takes the damage first. Alcohol-related liver disease is not a single event; it is a spectrum that usually advances over years:
- Steatosis (fatty liver). Fat accumulates in liver cells; at this stage the liver can return to normal with abstinence.
- Alcohol-associated hepatitis. Inflammation develops, sometimes abruptly and severely.
- Fibrosis. Persistent inflammation lays down scar tissue. Early fibrosis can stabilize or partially reverse when the cause is removed.
- Cirrhosis. Scar tissue replaces healthy liver tissue and the architecture of the organ is distorted. NIDDK defines it plainly: the liver is scarred and permanently damaged, and as it worsens the liver begins to fail.
Cirrhosis is not rare. NIDDK estimates that about 1 in 400 adults in the United States has it, and that the real number is probably higher because many people with early cirrhosis have no symptoms and are never diagnosed. Alcohol is one of the four most common causes, alongside fatty liver disease, chronic hepatitis C and chronic hepatitis B — and causes stack. Someone with hepatitis C who also drinks heavily or carries excess weight is not adding risks; they are multiplying them.
Compensated and Decompensated: The Distinction That Changes Everything
Transplant teams do not treat cirrhosis as one condition. They ask whether it is compensated or decompensated, because that distinction — not the word "cirrhosis" — drives prognosis and candidacy.
Compensated cirrhosis means the liver is scarred but still doing its jobs. There may be fatigue, poor appetite, itchy skin, or no symptoms at all; NIDDK notes that symptoms often appear only after the liver is badly damaged.
Decompensated cirrhosis means one of the specific failure events has occurred: ascites (fluid in the abdomen), variceal bleeding (bleeding from enlarged veins in the esophagus or stomach), or overt hepatic encephalopathy (confusion caused by toxins the liver can no longer clear). Each is treatable, and treating them keeps someone alive long enough to be evaluated. Decompensation can be followed by infection, kidney injury and progressive malnutrition and frailty, which is why teams weigh nutrition and physical function as seriously as lab values.
Two patterns matter because they move fast. Severe alcohol-associated hepatitis is an acute inflammatory crisis, commonly defined by a Maddrey discriminant function of at least 32 and/or a MELD score above 20, with reported mortality of roughly 18.5% at 28 days and 37.7% at six months. Acute-on-chronic liver failure adds organ failure and carries the highest short-term risk of all.
Why Stopping Drinking Is a Treatment, Not a Rule
Families hear "he has to stop drinking" as a precondition imposed by a committee. It is better understood as the most powerful intervention available.
In a 17-center cohort of 633 patients with decompensated alcohol-related cirrhosis, 31.1% achieved abstinence-induced recompensation, with cumulative incidences of 12.3%, 23.4% and 33.8% at one, two and five years. Recompensation is a defined clinical state, not vague improvement: under Baveno VII criteria it requires sustained abstinence, resolution of ascites without diuretics, resolution of hepatic encephalopathy without lactulose or rifaximin, and no recurrent variceal bleeding, held for at least 12 months with stable improvement in liver function. The scar does not disappear, but the person can stop behaving like a transplant candidate.
That is why delisting is a real outcome. Improvement-related removal from the waiting list has been reported in roughly 2% to 16% of candidates with alcohol-related liver disease depending on the program; US registry studies put it at 8.1% to 8.3%, and in one series 76% of delisted patients remained free of liver-related death or transplant five years later.
The "Six-Month Rule": What It Is and What It Is Not
It is not federal law. Organ allocation runs through the Organ Procurement and Transplantation Network, but candidacy criteria are set by each center's selection committee. NIDDK states this directly: each transplant center has its own guidelines about who can get a liver transplant, and centers often publish those guidelines on their websites. Listing requirements in 2026 remain genuinely heterogeneous.
It is losing its standing as a predictor. A 2026 review of transplantation for alcohol-related liver disease concludes that the traditional six-month rule "has limited value as a stand-alone predictor of harmful post-transplant alcohol use," and that guidance increasingly favors individualized multidisciplinary assessment of AUD severity, psychiatric comorbidity, social vulnerability, insight and treatment engagement. An intention-to-treat analysis of living donor transplantation published in 2025 puts it more bluntly: six months of abstinence is no longer a criterion for patients with alcohol-related liver disease.
It has not disappeared from practice. Many programs still want documented abstinence before listing someone with decompensated cirrhosis, because abstinence predicts improvement and lets the team observe whether the person can engage with treatment. What changed is that the number is no longer a magic threshold, and the early-transplant pathway bypasses it entirely in selected patients.
So: ask the center for its written criteria. Not the version summarized on the phone — the document the selection committee actually uses. Programs differ on abstinence, cannabis, prior treatment attempts and how they weigh social support. That is a reason to ask, not a reason to accept one hospital's answer as the national rule.
Severe Alcohol-Associated Hepatitis: When the Timeline Collapses
For most people with cirrhosis the transplant conversation is measured in months. For severe alcohol-associated hepatitis it is measured in days, and the evidence here is among the strongest in transplant medicine.
The pivotal 2011 trial by Mathurin and colleagues enrolled 26 patients at seven centers with a first episode of severe alcoholic hepatitis and no response to medical therapy (Lille score of 0.45 or higher; median in the trial 0.88), plus supportive family and a commitment to abstinence. Cumulative six-month survival was 77% among those who received early transplant versus 23% among matched patients who did not. Fewer than 2% of patients admitted for severe alcoholic hepatitis were selected, and the centers used 2.9% of available grafts for the indication. The ACCELERATE-AH consortium later reported 94% one-year and 84% three-year survival among 147 early-transplant recipients.
Non-response is measured, not guessed: patients typically receive corticosteroids and the Lille score is calculated after four to seven days, with steroids stopped in non-responders. And selection is deliberately narrow — first episode, no severe coexisting disease, demonstrable social support. This is not a loophole for skipping a waiting period; it is a rescue pathway for a group whose six-month mortality without transplant approaches 40%.
If someone is hospitalized with severe alcohol-associated hepatitis right now, ask the team directly: is this patient being considered for early transplant, and if not, why not? Not every hospital offers it.
How the Evaluation Actually Works
The evaluation is not an interview; it is a weeks-to-months process, and the team's composition tells you what is assessed.
NIDDK lists the roles: a transplant coordinator who is your point of contact, surgeons, a hepatologist, an insurance case manager, a financial coordinator, a social worker, a psychiatrist and a dietitian. Testing covers blood and urine tests, imaging, and heart, lung and kidney function. The team is really asking how likely this person is to survive surgery, what else is going on medically, and whether they and their caregivers can sustain the care that follows.
Some conditions make transplant less likely to succeed, and NIDDK names them: severe infection, alcohol or drug use problems, cancer outside the liver, and serious heart or lung disease. Notice where alcohol sits on that list — among the medical conditions that change the odds, not as a moral judgment. The team also assesses whether the person can follow instructions after transplant, and whether a real support system exists.
The psychosocial assessment is what families find most opaque. Programs often use structured instruments such as the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT), which organizes readiness, support, psychiatric stability, lifestyle and substance-use risk — but SIPAT is not alcohol-specific, no universal cut-off has been validated, and the 2026 review is explicit that no single score should determine candidacy.
You will also meet alcohol biomarkers, and it helps to know what each measures:
- PEth (whole blood) reflects recent exposure over weeks. Many programs treat less than 20 ng/mL as compatible with no or low recent exposure and at least 200 ng/mL as suggesting repeated moderate-to-heavy use, though cut-offs are not universal. Packed red cell transfusion can cause a false positive for over two weeks.
- Urine EtG generally reflects the previous one to three days; hair EtG covers months, where 5 pg/mg or less does not contradict abstinence and at least 30 supports chronic excessive consumption.
The review states plainly that no biomarker should be used alone to deny listing. Biomarkers are a monitoring tool, not a lie detector — and gaming them is the fastest way to lose a team's trust.
The Score That Decides Urgency
Once someone is listed, deceased-donor livers are allocated by a score, not by waiting time. The current US system is MELD 3.0, a refinement of the original score that incorporates additional factors to produce a more accurate three-month estimate of death without transplant.
Two practical consequences. Where you list matters: NIDDK notes that UNOS policies allow a patient to register with more than one transplant center to increase the chance of receiving a liver, with a separate evaluation at each. Programs differ in waitlist pressure and written criteria — a second listing is standard practice in many parts of the country.
Living donation is a real option to raise. In an intention-to-treat analysis of 233 patients with alcohol-related liver disease, 12% pursued primary living donor transplantation. Three-year overall survival was not significantly different from deceased-donor listing, and no patient in the living-donor group was delisted, versus 42% in the deceased-donor group — most often because of death or deterioration while waiting. Living donation is major surgery for the donor and not available to everyone, but it is worth asking rather than assuming the answer is no.
Medication for Alcohol Use Disorder When the Liver Is Sick
This is the section families most often never hear, and the one where a direct question can change the plan.
AUD is treatable with medication, and cirrhosis does not automatically rule that out — it changes which medication:
- Baclofen is the only medication with randomized trial evidence specifically in cirrhosis, with limited hepatic metabolism. Cautions: sedation, dizziness, encephalopathy risk and renal clearance.
- Acamprosate has minimal hepatic metabolism and preliminary data suggest acceptable tolerability, though efficacy data remain limited. Reduce the dose when creatinine clearance is 30 to 50 mL/min; avoid at 30 mL/min or lower.
- Naltrexone is effective in the general AUD population and may be considered in selected patients with stable liver function. Avoid in alcohol-associated hepatitis or severe decompensation; contraindicated with current opioid use or anticipated perioperative opioids.
- Gabapentin and topiramate are off-label options with renal dose adjustment and cautions around sedation and encephalopathy. Disulfiram should be avoided because of hepatotoxicity.
A 2026 randomized trial has begun to move the naltrexone line. In the NAL-CI trial, 100 patients with compensated alcohol-associated cirrhosis received naltrexone 50 mg daily or placebo for 12 weeks, with psychosocial support in both arms. Abstinence at 12 weeks was 64% with naltrexone versus 22% with placebo — roughly threefold — with reduced craving and no hepatic safety signal. That is one trial in a carefully defined population (compensated disease, mean MELD around 12.6), and it does not license naltrexone in acute hepatitis. But the older blanket statement that naltrexone is "contraindicated in liver disease" is out of date and worth raising with a hepatologist.
The larger problem is uptake, not evidence: pharmacotherapy is underused in alcohol-related liver disease because of limited insight, stigma, provider inexperience and fragmented care. Ask for an addiction medicine consult during the evaluation, not after it.
After a Transplant: What the Numbers Actually Say
A meta-analysis restricted to liver recipients with alcohol-related liver disease — more than 8,000 patients across 92 studies, mean follow-up about four years — estimated rates of any post-transplant alcohol use at 22% and heavy use at 14%. The honest summary: most recipients do not return to heavy drinking, and a substantial minority use alcohol at some point.
What predicts outcomes is the pattern, not any single drink. The ACCELERATE-AH cohort identified four trajectories — abstinent, late non-heavy, early non-heavy and early heavy use — with five-year survival of 95%, 100%, 62% and 53% respectively. Younger age, multiple previous rehabilitation attempts and pre-transplant overt hepatic encephalopathy were associated with early use.
And here is the finding every family should keep: among recipients who had harmful alcohol use and then achieved sustained reabstinence, adjusted predicted five-year survival was 94%, essentially identical to the 93% of recipients with no harmful use at all — compared with 77% among those with continued harmful use. A return to drinking after transplant is a medical event requiring intensified treatment, not the end of the story. What kills people is sustained harmful use and disengagement from care.
The 2026 review makes a language point worth adopting at home: avoid the word "relapse" in favor of describing patterns of use and their consequences. Shame is what makes people skip appointments.
What Families Can Do — Starting This Week
- Get a hepatology referral now, not after detox. Ask for a MELD score and an explanation of it.
- Request the center's written selection criteria, and compare two or three programs on abstinence, cannabis policy, psychosocial criteria and living-donor availability.
- Ask what counts as evidence of abstinence — which biomarker, over what window — and get the testing schedule in writing.
- Ask for addiction medicine involvement during the evaluation, and which AUD medication the team recommends given the liver function.
- Register at more than one center if logistics allow, and ask about living donation if there is a willing adult with an emotional tie to the patient.
- Talk to the financial coordinator early. NIDDK lists an insurance case manager and a financial coordinator on the team and notes that financial assistance programs exist for the surgery, medicines and follow-up care.
- Write the care plan down — who drives, who holds the medication list, where the person will live, who covers follow-up. The team is assessing whether that plan exists.
- Treat the abstinence period as treatment, not a countdown. Therapy, medication, peer support and, where appropriate, an intensive outpatient program all count as engagement. See our guides to alcohol use disorder treatment and to detox and withdrawal management — sudden cessation in a heavy drinker can be medically dangerous — and check how to verify coverage before the evaluation bill arrives.
What Backfires
- Managing the story. Biomarkers, collateral interviews and pharmacy records are part of the assessment. Concealment reads as poor insight, which is a criterion.
- Staging a confrontation during an acute illness. Nobody consents well to anything from a hospital bed in pain.
- Promising abstinence on someone else's behalf. Families can promise their own support; they cannot promise another adult's drinking. Nor should they become the abstinence police — searching bags and testing without consent produces hiding, not sobriety.
- Shopping for a program that lists without treating. A center that offers a transplant and no AUD plan is not a shortcut; it is the setup for the 14% who return to heavy drinking.
- Assuming six months sober means cured. It doesn't — and one drink after transplant is not the end of the story either.
Where to Get Help
- SAMHSA National Helpline — 1-800-662-4357. Free, confidential, 24/7, English and Spanish, with referrals for uninsured and underinsured callers.
- FindTreatment.gov — searchable directory of licensed facilities by location, payment type and service.
- 988 Suicide and Crisis Lifeline — call or text 988 for a mental health crisis, including suicidal thoughts that often accompany end-stage illness and AUD.
- 911 — for confusion that comes on suddenly, vomiting blood, black stools, or a person who cannot be woken.
If a loved one is drinking heavily and considering stopping, the detox guide explains why medical supervision matters. If they are refusing care altogether, this guide on refusing treatment is a more useful starting point than an ultimatum.
Bottom Line
Alcohol-related cirrhosis is a serious, often progressive disease — and in a meaningful share of patients it responds to the one thing families can actually influence: sustained abstinence, supported by medication and treatment rather than willpower alone. The six-month rule is program policy, not law, and many centers are replacing it with a structured assessment of whether someone can stay well after surgery. Families have more leverage than they think: ask for written criteria, ask for addiction medicine during the evaluation, ask about living donation and a second listing, and ask which medication fits a scarred liver.
Ask early. The liver does not wait for the family to finish arguing.
Sources
- NIDDK — Cirrhosis (National Institute of Diabetes and Digestive and Kidney Diseases)
- NIDDK — The Liver Transplant Process
- Ferrarese A, et al. Liver Transplantation for Alcohol-Related Liver Disease in 2026: Phenotypes, Selection, and Post-Transplant Care. J Clin Med. 2026;15(20):7840
- Mathurin P, et al. Early Liver Transplantation for Severe Alcoholic Hepatitis. N Engl J Med. 2011;365:1790-1800
- Alla M, et al. Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol-Associated Cirrhosis: NAL-CI Trial. Liver Int. 2026
- Magyar CTJ, et al. Living Donor Liver Transplantation for Alcohol-related Liver Disease: An Intention-to-treat Analysis. Transplantation. 2025
- Sharma Y, Fischbach C, Asrani SK. The liver allocation landscape: MELD 3.0 and continuous distribution. Curr Opin Organ Transplant. 2025
- SAMHSA — National Helpline
- SAMHSA — FindTreatment.gov
You might also read


